Show simple item record

dc.contributor.authorPinedo, H M
dc.contributor.authorBramwell, Vivien H C
dc.contributor.authorMouridsen, H T
dc.contributor.authorSomers, R
dc.contributor.authorVendrik, C P
dc.contributor.authorSantoro, A
dc.contributor.authorBuesa, J
dc.contributor.authorWagener, T
dc.contributor.authorVan Oosterom, A T
dc.contributor.authorVan Unnik, J A
dc.date.accessioned2011-03-12T23:41:42Zen
dc.date.available2011-03-12T23:41:42Zen
dc.date.issued1984-05-01en
dc.identifier.citationCyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group. 1984, 53 (9):1825-32 Canceren
dc.identifier.issn0008-543Xen
dc.identifier.pmid6367947en
dc.identifier.doi10.1002/1097-0142(19840501)53:9<1825::AID-CNCR2820530904>3.0.CO;2-Zen
dc.identifier.urihttp://hdl.handle.net/10541/124391en
dc.description.abstractTwo hundred forty-six adults with advanced progressive soft tissue sarcoma received combination chemotherapy with cyclophosphamide, vincristine, Adriamycin (doxorubicin), and DTIC. They were randomly allocated to receive the four drugs simultaneously every 4 weeks (S1: CYVADIC), or pairs of drugs (S2: ADIC-CYV) alternating at 4 weekly intervals. One hundred sixty-two patients completed 8 weeks of chemotherapy, and were considered to be evaluable for response. There were 18 complete remissions and 25 partial remissions, an overall response rate of 26%, with a highly significant difference between the two arms in favor of S1 (38% versus 14%, P = 0.001). There were no significant differences between S1 and S2 in terms of median duration of remissions (62 versus 39 weeks), and median survival of responders (85 versus 80 weeks) and of all evaluable patients (43 versus 45 weeks). Karnofsky index (KI) was the single most important prognostic factor. Patients with KI 90-100 showed a remission rate of 41% (56% on the S1 regimen) in contrast with 14% in those with KI 50-80. No patient with a KI of 50 responded to chemotherapy. The main toxicities were nausea, vomiting, anorexia, alopecia and myelosuppression, but did not differ significantly between the two regimens. Our findings suggest that stratification according to KI is essential for studies on chemotherapy for advanced soft tissue sarcomas in order to make a valuable comparison of treatment results.
dc.language.isoenen
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAntineoplastic Combined Chemotherapy Protocolsen
dc.subject.meshClinical Trials as Topicen
dc.subject.meshCyclophosphamideen
dc.subject.meshDacarbazineen
dc.subject.meshDoxorubicinen
dc.subject.meshFemaleen
dc.subject.meshFollow-Up Studiesen
dc.subject.meshHumansen
dc.subject.meshLeukopeniaen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshPrognosisen
dc.subject.meshRandom Allocationen
dc.subject.meshSarcomaen
dc.subject.meshSoft Tissue Neoplasmsen
dc.subject.meshThrombocytopeniaen
dc.subject.meshVincristineen
dc.titleCyvadic in advanced soft tissue sarcoma: a randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone Sarcoma Group.en
dc.typeArticleen
dc.identifier.eissn1097-0142en
dc.contributor.departmentDepartment of Medical Oncology, Free University Hospital and Netherlands Cancer Institute, Manchester, United Kingdomen
dc.identifier.journalCanceren
html.description.abstractTwo hundred forty-six adults with advanced progressive soft tissue sarcoma received combination chemotherapy with cyclophosphamide, vincristine, Adriamycin (doxorubicin), and DTIC. They were randomly allocated to receive the four drugs simultaneously every 4 weeks (S1: CYVADIC), or pairs of drugs (S2: ADIC-CYV) alternating at 4 weekly intervals. One hundred sixty-two patients completed 8 weeks of chemotherapy, and were considered to be evaluable for response. There were 18 complete remissions and 25 partial remissions, an overall response rate of 26%, with a highly significant difference between the two arms in favor of S1 (38% versus 14%, P = 0.001). There were no significant differences between S1 and S2 in terms of median duration of remissions (62 versus 39 weeks), and median survival of responders (85 versus 80 weeks) and of all evaluable patients (43 versus 45 weeks). Karnofsky index (KI) was the single most important prognostic factor. Patients with KI 90-100 showed a remission rate of 41% (56% on the S1 regimen) in contrast with 14% in those with KI 50-80. No patient with a KI of 50 responded to chemotherapy. The main toxicities were nausea, vomiting, anorexia, alopecia and myelosuppression, but did not differ significantly between the two regimens. Our findings suggest that stratification according to KI is essential for studies on chemotherapy for advanced soft tissue sarcomas in order to make a valuable comparison of treatment results.


This item appears in the following Collection(s)

Show simple item record